NCT01609010View on ClinicalTrials.gov

A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

PHASE3CompletedINTERVENTIONAL
Enrollment

313

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Lymphoma
Interventions
DRUG

rituximab

375 mg/m2 rituximab i.v. weekly for 4 weeks

DRUG

interferon-a-2a

3 MIU/day interferon-a2a s.c. during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5

Trial Locations (31)

2100

Copenhagen

3400

Hillerød

4000

Roskilde

4068

Stavanger

5021

Bergen

7000

Trondheim

9038

Tromsø

14186

Huddinge

17176

Stockholm

21401

Malmo

22185

Lund

29185

Kristianstad

30185

Halmstad

35185

Vaxjo

41685

Gothenburg

45180

Uddevalla

55185

Jönköping

58185

Linköping

62184

Visby

63188

Eskilstuna

65185

Karlstad

72189

Västerås

75185

Uppsala

79182

Falun

85186

Sundsvall

90185

Umeå

0379

Oslo

0407

Oslo

S-971 80

Luleå

701 85

Örebro

118 83

Stockholm

All Listed Sponsors
collaborator

Nordic Lymphoma Group

NETWORK

lead

Hoffmann-La Roche

INDUSTRY

NCT01609010 - A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma | Biotech Hunter | Biotech Hunter